mCRPC

You have access
Prognostic Stratification Using Early Prostate-specific Antigen Kinetics in Men With Metastatic Hormone-sensitive Prostate Cancer
TASUKU HIROSHIGE, HIROKI SUEKANE, TAKAHO TOKUNAGA, MAMI UEGAKI, MASAHITO IWASHITA, HIROKI TAURA, TAISHI HIRANO, TOMOTARO MITANI, MITSUNORI MATSUO and TSUKASA IGAWA

Anticancer Research February 2025, 45 (2) 751-759; DOI: https://doi.org/10.21873/anticanres.17463
You have access
MAOA Inhibitor Plus Docetaxel in Patients Receiving and Progressing on Docetaxel Therapy
TAYLOR AMERY, SHAADI TABATABAEI, MAYA SONPATKI, EVAN Y. YU and TOMASZ M. BEER

Anticancer Research May 2024, 44 (5) 2247-2248; DOI: https://doi.org/10.21873/anticanres.17033
You have access
PARP Inhibitors in Prostate Cancer
KABIR GREWAL, KAYANAAT GREWAL and IMAD A. TABBARA

Anticancer Research February 2021, 41 (2) 551-556; DOI: https://doi.org/10.21873/anticanres.14807
You have access
Biweekly Cabazitaxel Is a Safe Treatment Option for Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients After Docetaxel – A Final Analysis of the Prosty II Trial
PIRKKO-LIISA KELLOKUMPU-LEHTINEN, TIMO MARTTILA, ANTTI JEKUNEN, PETTERI HERVONEN, KATARIINA KLINTRUP, VESA KATAJA, TAPIO UTRIAINEN, MARJAANA LUUKKAA, MARKKU LESKINEN, KALEVI PULKKANEN, ANNA-LIISA KAUTIO and TEPPO HUTTUNEN

Anticancer Research December 2020, 40 (12) 6915-6921; DOI: https://doi.org/10.21873/anticanres.14715

Main menu